QRG Capital Management Inc. Grows Stock Position in Thermo Fisher Scientific Inc. $TMO

QRG Capital Management Inc. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 66.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 21,596 shares of the medical research company's stock after buying an additional 8,653 shares during the quarter. QRG Capital Management Inc.'s holdings in Thermo Fisher Scientific were worth $12,514,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. JPL Wealth Management LLC purchased a new stake in Thermo Fisher Scientific during the third quarter worth about $28,000. Beacon Financial Strategies CORP purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $29,000. Olistico Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $29,000. Cloud Capital Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the third quarter worth approximately $31,000. Finally, KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Thermo Fisher Scientific during the third quarter worth approximately $38,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the business's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,800 shares of company stock worth $2,963,544 over the last quarter. Insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Morgan Stanley reaffirmed an "overweight" rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating on the stock in a research report on Friday, April 24th. DZ Bank assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a "buy" rating and a $610.00 price objective on the stock. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a report on Friday, April 24th. Finally, UBS Group reaffirmed a "neutral" rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Buy" and an average target price of $623.05.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $466.74 on Wednesday. The business's 50 day simple moving average is $495.23 and its 200-day simple moving average is $547.61. The firm has a market capitalization of $173.45 billion, a price-to-earnings ratio of 25.66, a price-to-earnings-growth ratio of 2.05 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company's quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were given a $0.47 dividend. The ex-dividend date was Friday, March 13th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's payout ratio is presently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.